GlaxoSmithKline Offering Free Access to Potential Malaria Compounds
Executive Summary
In another effort to boost development of malaria medicines GlaxoSmithKline is providing free public access to its library of 13,500 compounds that have shown some activity against the disease
You may also be interested in...
GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
GSK Prepares For Malaria Vaccine Roll-Out In Africa By 2015
“While we have seen some decline in vaccine efficacy over time, the sheer number of children affected by malaria means that the number of cases of the disease the vaccine can help prevent is impressive,” GSK CEO Witty says.
Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.